US FDA's Dietary Supplement Programs Deserve A Raise, Trade Groups Tell Senate Appropriators
Compliant industry drove US market growth to $55bn in 2020, and faster growth and higher sales are ahead if FDA’s Office of Dietary Supplement Programs has sufficient funding to eliminate non-compliant businesses.
You may also be interested in...
CDER compliance office director Donald Ashley offers a cautionary note to temper expectations for the FDA’s enforcement in the supplement sector. “We continue to warn the public about products very often sold as dietary supplements that contain hidden drugs,” he says.
Acting commissioner's comment on supplement industry regulation was her most definitive statement about the agency’s work in consumer health sector at CHPA's regulatory conference. Pandemic, she says, heightened consumer interest in self-care along with demand for OTC drugs and supplements.
Appropriation set for CFSAN and ORA’s related field activities is $1.16bn, up slightly from the FY2021 level of $1.1bn, and for CDER and ORA’s related activities is $2.1bn, up $100m from current funding.